Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
EMA validates Pfizer-Astellas’ bladder cancer therapy application for review
The European Medicines Agency (EMA) has validated for review a Type II variation application for Pfizer and Astellas Pharma’s PADCEV (enfortumab vedotin) with KEYTRUDA (pembrolizumab) as first-line therapy option for locally advanced or metastatic urothelial cancer (la/mUC).
